title: Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues.
abstract: To investigate epidermal growth factor receptor (EGFr) presence in the prostate, monoclonal antibody (clone EGFR1) immunohistochemical examination of radical prostatectomy specimens was performed (n = 37). All prostatic specimens contained benign prostatic hyperplasia (BPH) and/or dysplasia (prostatic intraepithelial neoplasia or PIN), as well as prostatic carcinoma (CaP). Areas of dysplasia were further categorized as to the basal cell layer and the luminal cell area. BPH, PIN, and CaP tissues in each specimen were analyzed by a single observer and graded on a scale from 0-4+. Fifteen samples were also analyzed for EGFr content utilizing a Cell Analysis Systems (CAS 200) image cytometer. EGFr immunoreactivity of BPH basal cells was significantly higher than EGFr immunoreactivity in areas of CaP (p < 0.001). EGFr staining of BPH basal cells was also significantly higher than that seen in PIN luminal cells (p < 0.001). Immunoreactivity of EGFr in PIN basal cells was significantly higher than in PIN luminal cells (p < 0.001). EGFr staining of basal cells in BPH tissues was higher than that seen in the PIN basal cell layer but the difference was not statistically significant (p = 0.06). The amount of staining present in PIN luminal cells was also significantly greater than in CaP tissues (p = 0.002). Quantitative image analysis utilizing the CAS 200 image cytometer was performed on BPH and CaP areas exclusively. EGFr immunoreactivity in basal cells of the BPH tissues was significantly greater than that seen in CaP tissues (p < 0.001). The decreased EGFr immunoreactivity in CaP may reflect a differentiating role for EGFr in normal tissues. Loss of EGFr influence may be associated with an increased proliferative state in PIN and CaP. Destruction or alteration of the epidermal grwoth factor receptor by a protease, such as prostatic specific antigen, may also explain our findings. At the present time the meaning of the different amounts of EGFr in the various types of prostate tissues is unknown.
authors.affiliation: Division of Urology, Duke University Medical Center, Durham, North Carolina.
authors.forename: G K
authors.initials: GK
authors.lastname: Ibrahim
authors.forename: B J
authors.initials: BJ
authors.lastname: Kerns
authors.forename: J A
authors.initials: JA
authors.lastname: MacDonald
authors.forename: S N
authors.initials: SN
authors.lastname: Ibrahim
authors.forename: R B
authors.initials: RB
authors.lastname: Kinney
authors.forename: P A
authors.initials: PA
authors.lastname: Humphrey
authors.forename: C N
authors.initials: CN
authors.lastname: Robertson
mesh_terms: D000368:Aged; D003937:Diagnosis, Differential; D066246:ErbB Receptors / Q000032:analysis* / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000473:pathology*
chemical_list: D066246:ErbB Receptors